NRTI

DRUG3 trials

Sponsors

Gilead Sciences, Assembly Biosciences, Vir Biotechnology, Inc.

Conditions

Acquired Immunodeficiency SyndromeChronic Hepatitis BHIV InfectionsHepatitis D, Chronic

Phase 2

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

TerminatedNCT04454567

Assembly BiosciencesChronic Hepatitis B

Start: 2020-11-11End: 2021-04-08Updated: 2022-10-20

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Active, not recruitingNCT05461170

Vir Biotechnology, Inc.Hepatitis D, Chronic

Start: 2022-09-17End: 2029-08-31Updated: 2025-10-14

Phase 3

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

CompletedNCT01363011

Gilead SciencesAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2011-05-31End: 2015-02-28Updated: 2016-05-02

Related Papers

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

2025-11-091 citations